Find Oncology Drugs in Phase II Clinical Development in JAPAN

Lead Product(s): Trastuzumab Deruxtecan

Therapeutic Area: Oncology

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 27, 2020

Details:

Trial met primary endpoint of objective response rate and key secondary endpoint of overall survival in patients with previously treated HER2 positive metastatic gastric cancer.

Lead Product(s): CH5126766,Defactinib

Therapeutic Area: Oncology

Highest Development Status: Phase II Product Type: Undisclosed

Partner/Sponsor/Collaborator: Verastem Oncology

Deal Size: Undisclosed Upfront Cash: $3.0 million

Deal Type: Licensing Agreement January 08, 2020

Details:

Under the terms of the agreement, Verastem Oncology is responsible for the development and worldwide commercialization of CH5126766.